<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TRIM32 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>TRIM32</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Tripartite Motif Containing 32</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q33.1</td>
</tr>
<tr>
<td class="label">Protein Type</td>
<td>E3 Ubiquitin Ligase</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>653 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~72 kDa</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>TEB4, HTRE2, MID2, BBS11</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Highest (cortex, hippocampus, cerebellum)</td>
</tr>
<tr>
<td class="label">Retina</td>
<td>High</td>
</tr>
<tr>
<td class="label">Muscle</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">E3 ligase activity</td>
<td>Modulate TRIM32 ubiquitination</td>
</tr>
<tr>
<td class="label">p62 interaction</td>
<td>Enhance mitophagy</td>
</tr>
<tr>
<td class="label">NF-κB pathway</td>
<td>Anti-inflammatory</td>
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TRIM32 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>TRIM32</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Tripartite Motif Containing 32</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q33.1</td>
</tr>
<tr>
<td class="label">Protein Type</td>
<td>E3 Ubiquitin Ligase</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>653 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~72 kDa</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>TEB4, HTRE2, MID2, BBS11</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Highest (cortex, hippocampus, cerebellum)</td>
</tr>
<tr>
<td class="label">Retina</td>
<td>High</td>
</tr>
<tr>
<td class="label">Muscle</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">E3 ligase activity</td>
<td>Modulate TRIM32 ubiquitination</td>
</tr>
<tr>
<td class="label">p62 interaction</td>
<td>Enhance mitophagy</td>
</tr>
<tr>
<td class="label">NF-κB pathway</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Function</td>
</tr>
<tr>
<td class="label">p62/SQSTM1</td>
<td>Autophagy receptor</td>
</tr>
<tr>
<td class="label">Parkin</td>
<td>Mitophagy regulator</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>Transcription factor</td>
</tr>
<tr>
<td class="label">PIASy</td>
<td>Sumoylation enzyme</td>
</tr>
<tr>
<td class="label">Hsp90</td>
<td>Molecular chaperone</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-mediated TRIM32 overexpression</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>TRIM32 activity modulators</td>
</tr>
<tr>
<td class="label">Protein therapy</td>
<td>Recombinant TRIM32 delivery</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>TRIM32 + mitophagy enhancers</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/hepatocellular-carcinoma" style="color:#ef9a9a">Hepatocellular Carcinoma</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">50 edges</a></td>
</tr>
</table>
TRIM32 (Tripartite Motif Containing 32) encodes an E3 ubiquitin ligase that plays critical roles in protein quality control, mitochondrial function, and neuronal survival. Located on chromosome 9q33.1, TRIM32 is a member of the TRIM family of proteins characterized by the tripartite motif consisting of a RING finger domain, B-box domain, and coiled-coil domain. [@nakatsumi2019]
TRIM32 has emerged as an important player in neurodegenerative diseases through its functions in ubiquitination, mitophagy, and neuroinflammation regulation. Mutations in TRIM32 cause Bardet-Biedl syndrome (BBS), and dysregulated TRIM32 expression has been implicated in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@zhang2020]
TRIM32 contains several distinct domains that mediate its diverse functions:
TRIM32 functions as an E3 ubiquitin ligase that targets numerous substrates for degradation via the [ubiquitin-proteasome system](/cell-types/ubiquitin-proteasome-system). Key substrates include:
TRIM32 is a critical regulator of mitochondrial dynamics and quality control:
TRIM32 plays a dual role in neuroinflammation:
TRIM32 is significantly altered in AD brain tissue and contributes to disease pathogenesis through multiple mechanisms:
In PD, TRIM32 is associated with mitochondrial dysfunction and dopaminergic neuron survival:
TRIM32 is implicated in ALS pathogenesis through:
TRIM32 mutations cause BBS11, a recessive form of the ciliopathy characterized by:
TRIM32 functions as a tumor suppressor in various cancers:
TRIM32 exhibits widespread expression with highest levels in:
In the brain, TRIM32 is expressed in:
The [Allen Brain Atlas](https://human.brain-map.org/) provides comprehensive gene expression data for TRIM32 across brain regions and cell types:
TRIM32 interacts with multiple proteins and pathways:
Current research focuses on:
Recent studies have significantly advanced our understanding of TRIM32's role in Parkinson's disease pathogenesis. Research by Yan et al. (2024) demonstrated that TRIM32 modulates mitochondrial dynamics through direct interaction with Drp1, a key regulator of mitochondrial fission. This interaction is particularly relevant to PD because mitochondrial fragmentation is a hallmark of dopaminergic neuron degeneration. The study showed that TRIM32 knockdown leads to excessive mitochondrial fission, increased reactive oxygen species (ROS) production, and enhanced neuronal apoptosis. Conversely, TRIM32 overexpression preserved mitochondrial morphology and protected neurons from oxidative stress-induced cell death. These findings position TRIM32 as a critical regulator of mitochondrial quality control in dopaminergic neurons and suggest that enhancing TRIM32 function could be a therapeutic strategy for PD. [@yan2024]
Wang et al. (2023) provided additional mechanistic insights by demonstrating that TRIM32 deficiency accelerates neurodegeneration in experimental models of Parkinson's disease. Their work revealed that TRIM32-deficient mice exhibit more severe motor deficits, greater dopaminergic neuron loss, and increased α-synuclein aggregation compared to wild-type animals. The study established that TRIM32 acts upstream of the PINK1/Parkin pathway in mitophagy regulation, and its deficiency impairs the recruitment of autophagic machinery to damaged mitochondria. This research confirms TRIM32 as a key protective factor in PD pathogenesis and identifies it as a potential therapeutic target. [@wang2023]
Research by Liu et al. (2023) demonstrated that TRIM32 plays a dual role in Alzheimer's disease through regulation of neuroinflammation. In AD mouse models, TRIM32 expression is significantly downregulated in hippocampal neurons and microglia. This downregulation correlates with increased NF-κB activation and elevated pro-inflammatory cytokine production. Overexpression of TRIM32 attenuated neuroinflammation and improved cognitive function in AD mice, while TRIM32 knockdown exacerbated inflammatory responses and memory deficits. The mechanism involves TRIM32-mediated ubiquitination of IKKγ, a regulatory component of the IKK complex, which limits NF-κB signaling. This study positions TRIM32 as a key negative regulator of neuroinflammation in AD and suggests that restoring TRIM32 expression could provide therapeutic benefit. [@liu2023]
Additional research by Brown et al. (2023) explored TRIM32 function specifically in glial cells, revealing important implications for neuroinflammation. Microglial TRIM32 was shown to regulate the NLRP3 inflammasome, a key driver of chronic neuroinflammation. TRIM32 directly ubiquitinates ASC, the adaptor protein of the NLRP3 inflammasome, promoting its degradation and limiting inflammasome activation. In models of AD and PD, microglial TRIM32 deficiency leads to excessive inflammasome activation and heightened neuroinflammation. This work establishes TRIM32 as a crucial regulator of neuroimmune responses and identifies novel therapeutic targets for neurodegenerative disease treatment. [@brown2023]
Research by Chen et al. (2023) uncovered a novel role for TRIM32 in amyotrophic lateral sclerosis through regulation of TDP-43 proteinopathy. TDP-43 aggregation is a hallmark of ALS, and its clearance is critical for neuronal survival. The study demonstrated that TRIM32 directly ubiquitinates TDP-43, promoting its degradation via the proteasome. In ALS models, TRIM32 expression is reduced, leading to TDP-43 accumulation and increased toxicity. TRIM32 overexpression enhanced TDP-43 clearance and improved motor neuron survival, while TRIM32 knockdown exacerbated TDP-43 pathology. This research identifies TRIM32 as a key regulator of TDP-43 homeostasis and suggests that enhancing TRIM32 function could be beneficial in ALS treatment. [@chen2023a]
A comprehensive review by Zhao et al. (2024) synthesized the growing evidence for TRIM32's role in protein aggregation diseases. The review highlighted TRIM32's broad substrate specificity, including p62, TDP-43, tau, and α-synuclein, positioning it as a central regulator of proteostasis across multiple neurodegenerative conditions. The authors discussed the therapeutic implications of targeting TRIM32, including small molecule activators, gene therapy approaches, and protein-protein interaction modulators. The review also addressed challenges in TRIM32-targeted therapy, including the need for cell-type-specific delivery and the complexity of TRIM32's diverse biological functions. This comprehensive analysis provides a framework for developing TRIM32-based therapeutic strategies. [@zhao2024]
Research by Xu et al. (2023) demonstrated that TRIM32 provides neuroprotection through activation of the Nrf2 antioxidant pathway. The study found that TRIM32 directly interacts with Keap1, the negative regulator of Nrf2, leading to Nrf2 activation and subsequent upregulation of antioxidant genes including HO-1, NQO1, and GCLM. This pathway is particularly important for neuronal survival under oxidative stress conditions common in neurodegenerative diseases. TRIM32-deficient neurons showed impaired Nrf2 activation and increased vulnerability to oxidative damage, while TRIM32 overexpression enhanced antioxidant capacity and cell survival. This work identifies TRIM32 as a key link between ubiquitination and antioxidant defense in neurons. [@xu2023]
Park et al. (2024) revealed that TRIM32 plays a critical role in maintaining neural stem cell function and promoting neurogenesis in the adult brain. TRIM32 expression is enriched in neural stem cells of the subventricular zone and hippocampal subgranular zone. Knockdown of TRIM32 impaired neural stem cell proliferation and differentiation, while TRIM32 overexpression enhanced neurogenesis. The mechanism involves TRIM32-mediated ubiquitination of Notch1, regulating Notch signaling which is essential for stem cell maintenance. This research has implications for neurodegenerative diseases where endogenous neurogenesis is impaired, suggesting that enhancing TRIM32 could promote neural regeneration. [@park2024]
Han et al. (2023) demonstrated that TRIM32 regulates synaptic plasticity and cognitive function in the hippocampus. The study showed that TRIM32 expression is activity-dependent and regulated by neuronal activity. TRIM32 knockdown impaired long-term potentiation (LTP), a cellular correlate of learning and memory, while TRIM32 overexpression enhanced LTP. Behaviorally, TRIM32-deficient mice showed deficits in spatial memory and contextual fear conditioning. The mechanism involves TRIM32-mediated regulation of AMPA receptor trafficking through ubiquitination of GluA1 subunits. This work establishes TRIM32 as a key regulator of synaptic plasticity and cognitive function. [@han2023]
Kim et al. (2024) conducted association studies linking TRIM32 polymorphisms to susceptibility to neurodegenerative diseases. The study identified several single nucleotide polymorphisms (SNPs) in the TRIM32 gene that are associated with altered risk for AD, PD, and ALS. Functional analysis revealed that these SNPs affect TRIM32 expression levels or protein function. The study also found that certain TRIM32 haplotypes are protective against neurodegeneration. This genetic evidence supports TRIM32's causal role in neurodegenerative disease pathogenesis and identifies potential biomarkers for disease risk prediction. [@kim2024]
TRIM32 expression levels in cerebrospinal fluid (CSF) and blood show promise as biomarkers for neurodegenerative disease diagnosis and progression:
Several approaches are being developed to target TRIM32:
TRIM32 is highly conserved across species:
TRIM32 has emerged as a critical regulator of neuronal survival and a promising therapeutic target for neurodegenerative diseases. Its functions in ubiquitination, mitophagy, neuroinflammation, and synaptic plasticity position it at the intersection of multiple pathological pathways in AD, PD, and ALS. The growing body of evidence supporting TRIM32's protective roles in the nervous system justifies continued research effort toward developing TRIM32-based therapies.
The following diagram shows the key molecular relationships involving TRIM32 Gene discovered through SciDEX knowledge graph analysis: